Humanwell Healthcare Group Co Ltd
SSE:600079

Watchlist Manager
Humanwell Healthcare Group Co Ltd Logo
Humanwell Healthcare Group Co Ltd
SSE:600079
Watchlist
Price: 23.48 CNY -2.29%
Market Cap: 38.3B CNY
Have any thoughts about
Humanwell Healthcare Group Co Ltd?
Write Note

Humanwell Healthcare Group Co Ltd
Operating Income

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Humanwell Healthcare Group Co Ltd
Operating Income Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Operating Income CAGR 3Y CAGR 5Y CAGR 10Y
Humanwell Healthcare Group Co Ltd
SSE:600079
Operating Income
ÂĄ3.7B
CAGR 3-Years
11%
CAGR 5-Years
N/A
CAGR 10-Years
15%
H
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
Operating Income
ÂĄ2.6B
CAGR 3-Years
-2%
CAGR 5-Years
3%
CAGR 10-Years
N/A
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
Operating Income
ÂĄ3.5B
CAGR 3-Years
10%
CAGR 5-Years
20%
CAGR 10-Years
24%
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
Operating Income
ÂĄ5.8B
CAGR 3-Years
-3%
CAGR 5-Years
3%
CAGR 10-Years
14%
Yunnan Baiyao Group Co Ltd
SZSE:000538
Operating Income
ÂĄ4B
CAGR 3-Years
2%
CAGR 5-Years
9%
CAGR 10-Years
1%
S
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
Operating Income
-ÂĄ749.4m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Humanwell Healthcare Group Co Ltd
Glance View

Market Cap
38.3B CNY
Industry
Pharmaceuticals

In the rapidly evolving landscape of the Chinese pharmaceutical industry, Humanwell Healthcare Group Co Ltd. stands as a multifaceted player with its roots deeply embedded in both innovation and tradition. Founded in Wuhan, Humanwell has cultivated a robust portfolio that extends beyond the manufacture and distribution of pharmaceuticals, marking its presence in fields like anesthetics, reproductive health products, and specialty chemicals. Anchoring its operations is a commitment to research and development, investing significantly in new technologies and drug formulations. Humanwell leverages its extensive manufacturing capabilities and adheres to rigorous quality controls, enabling it to efficiently produce and market a diverse array of products across domestic and international markets. The company’s financial structure is bolstered by a savvy integration of its capabilities and strategic partnerships, enhancing both its market reach and product offerings. With subsidiaries spread across different continents, Humanwell taps into the lucrative supply chains of the healthcare sector, accentuating its revenue streams. Through strategic acquisitions and partnerships, the company has invested in expanding its global footprint, enhancing its competitive prowess. This tactical expansion, coupled with a keen focus on understanding and fulfilling consumer needs, allows Humanwell Healthcare not only to sustain a strong financial performance but also to play a pivotal role in shaping the future of the healthcare market in China and beyond.

Intrinsic Value
37.19 CNY
Undervaluation 37%
Intrinsic Value
Price

See Also

What is Humanwell Healthcare Group Co Ltd's Operating Income?
Operating Income
3.7B CNY

Based on the financial report for Sep 30, 2024, Humanwell Healthcare Group Co Ltd's Operating Income amounts to 3.7B CNY.

What is Humanwell Healthcare Group Co Ltd's Operating Income growth rate?
Operating Income CAGR 10Y
15%

Over the last year, the Operating Income growth was 11%. The average annual Operating Income growth rates for Humanwell Healthcare Group Co Ltd have been 11% over the past three years , and 15% over the past ten years .

Back to Top